Evaluation Of A Financial Incentive To Improve The Use Of Preventive Medicines By People With Asthma
Funder
National Health and Medical Research Council
Funding Amount
$137,860.00
Summary
Rising costs are threatening the future viability of the Pharmaceutical Benefits Scheme. New approaches are needed to address this challenge, including developing financial incentives for consumers to use effective low cost medicines in preference to higher cost alternatives. This study will develop a consumer incentive for use of low cost asthma preventer medicines, model the economic effects of this and bring together stakeholders to examine the policy and practice changes needed to implement ....Rising costs are threatening the future viability of the Pharmaceutical Benefits Scheme. New approaches are needed to address this challenge, including developing financial incentives for consumers to use effective low cost medicines in preference to higher cost alternatives. This study will develop a consumer incentive for use of low cost asthma preventer medicines, model the economic effects of this and bring together stakeholders to examine the policy and practice changes needed to implement the incentive.Read moreRead less
REGULATION OF GLUCOCORTICOID SENSITIVITY BY ANNEXIN-1
Funder
National Health and Medical Research Council
Funding Amount
$533,828.00
Summary
Steroids like prednisolone or cortisone are very effective at reducing inflammation in diseases like rheumatoid arthritis and are particularly known to decrease substances involved in inflammation. Almost 70% of patients with rheumatoid arthritis are treated more or less continuously with steroids. Steroid resistance (need for higher doses) or changes in steroid-sensitivity has been widely recognized in asthma, inflammatory bowel disease, and rheumatoid arthritis. Many new drug therapies however ....Steroids like prednisolone or cortisone are very effective at reducing inflammation in diseases like rheumatoid arthritis and are particularly known to decrease substances involved in inflammation. Almost 70% of patients with rheumatoid arthritis are treated more or less continuously with steroids. Steroid resistance (need for higher doses) or changes in steroid-sensitivity has been widely recognized in asthma, inflammatory bowel disease, and rheumatoid arthritis. Many new drug therapies however have the aim of keeping cortisone use to a minimum because of undesirable side effects like osteoporosis. Annexin-1 is an anti-inflammatory substance important in arthritis development which is also known to mediate many of the actions of steroids. However, the possible contribution of annexin-1 to mediate the effect of steroids in the regulation of these substances has not been examined. Moreover, how annexin-1 turns genes on is not known. Our studies will therefore reveal whether the absence of annexin-1 will increase inflammatory substances turn genes, and secondly, by determining the possible substances regulated by annexin-1 if the treatment with steroids are less effective in the absence of annexin-1. If annexin-1 is found either to increase anti-inflammatory substances or to mediate the effect of therapeutic steroids, its capacity to be involved in the beneficial effect of steroids may have an important impact in treatment of arthritis and other inflammatory diseases. If annexin-1 functionally acts as steroids, the reduction or discontinuation of steroid use will be possible.Read moreRead less
Comparative Effectiveness Of Ultrasound-guided Injection With Either Autologous Platelet Rich Plasma Or Glucocorticoid For Ultrasound-proven Lateral Epicondylitis: A Three-arm Randomised Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$518,631.00
Summary
Tennis elbow is a common condition affecting both men and women. It causes pain, disability, often inability to work and high health costs. The best treatment is uncertain but injection of a small quantity of a person’s own platelet rich plasma (PRP) appears to be a promising new treatment that has not yet been properly tested. We will perform a randomised, controlled trial to determine the efficacy, safety and cost-effectiveness of PRP injection to see if it is better than either placebo or cor ....Tennis elbow is a common condition affecting both men and women. It causes pain, disability, often inability to work and high health costs. The best treatment is uncertain but injection of a small quantity of a person’s own platelet rich plasma (PRP) appears to be a promising new treatment that has not yet been properly tested. We will perform a randomised, controlled trial to determine the efficacy, safety and cost-effectiveness of PRP injection to see if it is better than either placebo or corticosteroid injection.Read moreRead less
Local SAA Production Drives Glucocortosteriod Resistant Airway Inflammation In COPD
Funder
National Health and Medical Research Council
Funding Amount
$540,704.00
Summary
We have recently identified a blood marker termed SAA that is highly elevated during an acute attack of Chronic Obstructive Pulmonary Disease (COPD) mainly caused by chest infections. These episodes are a major cause of hospitalisation. Our previous studies suggest that by measuring blood SAA levels we can prevent a worsening of the attack with early intervention. We are now exploring the biological role of SAA and whether blocking SAA activity will benefit COPD patients.
A Randomised Control Trial Of Physiotherapy And Corticosteroid Injections Of Lateral Epicondylalgia In Primary Care.
Funder
National Health and Medical Research Council
Funding Amount
$193,775.00
Summary
Musculoskeletal conditions account for the third leading cause of health systems expenditure in Australia. Lateral epicondylalgia (tennis elbow) is such a condition and is often treated in primary care. Both the individual and community are affected by this condition: 7 per 1000 patients seeing their medical doctor have this condition. Most are not tennis related. On average 10-30% of sufferers take 12 weeks off work. The condition may last 6-48 months and it tends to become stubborn to treatmen ....Musculoskeletal conditions account for the third leading cause of health systems expenditure in Australia. Lateral epicondylalgia (tennis elbow) is such a condition and is often treated in primary care. Both the individual and community are affected by this condition: 7 per 1000 patients seeing their medical doctor have this condition. Most are not tennis related. On average 10-30% of sufferers take 12 weeks off work. The condition may last 6-48 months and it tends to become stubborn to treatment and recurs often. Two popular treatment options that are commonly prescribed for the management of lateral epicondylalgia are physiotherapy and corticosteroid injections. To date there is little evidence supporting physiotherapy, especially current best practice methods such as manual therapy and therapeutic exercise. The lack of evidence is largely due to a small number of studies of physiotherapy, most of which are of poor quality and of treatments that are currently deemed to be less than optimal. A larger number of studies of corticosteroid injections have shown that corticosteroid injections are beneficial in the short term (3-6 weeks), but not over 12 months where they are associated with greater recurrence rates. Manual therapy has been shown to have short term pain relieving effects and therapeutic exercise exerts long standing improvements in this condition. It is proposed that the addition of manual therapy to therapeutic exercise will have superior short- and long-term effects. This project will conduct a randomised clinical trial to evaluate this proposition and also the factors associated with success, failure or recurrence rates. A cost-benefit analysis will also be conducted to calculate the relative economic merits of the treatments. A tangible outcome of this project will be the development of clinical guidelines for the most effective method of treating lateral epicondylalgia in primary health care.Read moreRead less